Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ethambutol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | CNR1 | P21554 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.94 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.94 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | TRPV3 | Q8NET8 | 2/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethambutol SCHEMBL2636850 | 1.00 | LMNA (1.00) | LMNACNR1ADRA1ATDP1KDM4E | |
| Ethambutol SCHEMBL3399 | 1.00 | LMNA (1.00) | LMNACNR1ADRA1ATDP1KDM4E | |
| Ethambutol SCHEMBL2961583 | 1.00 | LMNA (1.00) | LMNACNR1ADRA1ATDP1KDM4E | |
| Ethambutol SCHEMBL4029 | 1.00 | LMNA (1.00) | LMNACNR1ADRA1ATDP1KDM4E | |
| Ethambutol SCHEMBL15479016 | 1.00 | LMNA (1.00) | LMNACNR1ADRA1ATDP1KDM4E | |
| Ethambutol SCHEMBL3026481 | 0.97 | ABCC3 (1.00) | LMNACNR1ADRA1ATDP1KDM4E | |
| Ethambutol SCHEMBL16416505 | 0.97 | LMNA (0.94) | LMNACNR1ADRA1ATDP1KDM4E | |
| Ethambutol SCHEMBL9949005 | 0.97 | ABCC3 (1.00) | LMNACNR1ADRA1ATDP1KDM4E | |
| Ethambutol SCHEMBL37049 | 0.97 | ABCC3 (1.00) | LMNACNR1ADRA1ATDP1KDM4E | |
| Ethambutol SCHEMBL650049 | 0.97 | ABCC3 (1.00) | LMNACNR1ADRA1ATDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116457354-A | Herbicidal pyrimidine derivatives | 摩雅科技有限公司 | 2023-07-18 | — | — | CN | disclosed |
| US-9555003-B2 | Oral solid formulation of compound anti-tubercular drug and preparation method thereof | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2017-01-31 | — | — | US | disclosed |
| EP-2782921-A1 | ORGANIC TUNGSTEN COMPLEXES | Vanderbilt Chemicals, LLC (US) | 2014-10-01 | — | — | EP | disclosed |
| US-20140127294-A1 | ORAL SOLID FORMULATION OF COMPOUND ANTI-TUBERCULAR DRUG AND PREPARATION METHOD THEREOF | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2014-05-08 | — | — | US | disclosed |
| WO-2013077948-A1 | ORGANIC TUNGSTEN COMPLEXES | VANDERBILT CHEMICALS, LLC. (US) | 2013-05-30 | — | — | WO | disclosed |
| US-8198303-B2 | Methods of use and compositions for the diagnosis and treatment of infectious diseases | SEQUELLA, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-8198303-B2 | Methods of use and compositions for the diagnosis and treatment of infectious diseases | SEQUELLA, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| WO-2012013848-A1 | DIFLUOROBENZYL ETHANOLAMINE DERIVATIVES WITH ANTIMICROBIAL ACTIVITY | FUNDACIÓN DE LA COMUNIDAD VALENCIANA "CENTRO DE INVESTIGACIÓN PRÍNCIPE FELIPE" (ES) | 2012-02-02 | — | — | WO | disclosed |
| US-7884097-B2 | Contains 1-(2-Aminoethyl)piperidine and 2-adamantanone; mycobacterial infections | SEQUELLA, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-20100273826-A1 | METHODS OF USE AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF INFECTIOUS DISEASES | SEQUELLA, INC. | 2010-10-28 | — | — | US | disclosed |
| US-20100273826-A1 | METHODS OF USE AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF INFECTIOUS DISEASES | SEQUELLA, INC. | 2010-10-28 | — | — | US | disclosed |
| US-7652039-B2 | Such as 1-(2-((3-(4-chlorophenoxy)benzyl)amino)-3-phenyl-propyl)piperidin-4-ol for treatment of tuberculosis; solid phase synthesis | SEQUELLA, INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-7652039-B2 | Such as 1-(2-((3-(4-chlorophenoxy)benzyl)amino)-3-phenyl-propyl)piperidin-4-ol for treatment of tuberculosis; solid phase synthesis | SEQUELLA, INC. (US) | 2010-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273826-A1 | METHODS OF USE AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF INFECTIOUS DISEASES | C5, THPO, TERT | LMNA 986/4885CNR1 3602/4885ADRA1A 3048/4885 |
| US-20140127294-A1 | ORAL SOLID FORMULATION OF COMPOUND ANTI-TUBERCULAR DRUG AND PREPARATION METHOD THEREOF | TPMT, CYP3A5, TST | LMNA 2226/4885CNR1 4801/4885ADRA1A 3526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.